Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine
Thomas C Heineman1, Anthony Cunningham2, Myron Levin3
1Halozyme Therapeutics, Clinical Development and Translational Medicine, 11388 Sorrento Valley Road, San Diego, CA 92121, United States.
Abstract:
Herpes zoster is common in older and immune suppressed persons due to diminished VZV-specific cellular immunity. A recombinant herpes zoster vaccine (RZV) consisting of a single VZV glycoprotein and an adjuvant system stimulates robust and persistent VZV-specific antibody and CD4+ T cell responses in these high-risk populations. VZV-specific immune responses induced by RZV, including the generation of polyfunctional T cells, are driven by the synergistic actions of the components of the vaccine adjuvant system. RZV provides unprecedented protection against herpes zoster in older adults regardless of age at vaccination and is efficacious in immune suppressed populations. Adjuvanted subunit antigens may represent a general strategy for vaccines in the elderly and other individuals typically considered immunologically resistant to vaccination.
More Related Videos
Related Concept Videos
Vaccinations
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
Understanding the Self
Recombinant DNA
Matrix Proteoglycans and Glycoproteins
Understanding Memory


